• Avelumab in High-Grade Neuroendocrine Tumors: Insights from the AveNEC Trial

    The Phase II AveNEC trial, published in Clinical Cancer Research (February 2025), evaluated avelumab in patients with high-grade neuroendocrine neoplasms (NEN G3) who had progressed after prior chemotherapy. The study…

  • BREAKWATER Phase 3 Trial: A New Standard for First-Line BRAF V600E-Mutant mCRC Treatment

    The BREAKWATER phase 3 trial, published in Nature Medicine, has demonstrated that encorafenib plus cetuximab (EC) with mFOLFOX6 significantly improves objective response rates compared to standard chemotherapy in BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study reports a confirmed objective response rate of 60.9% with EC+mFOLFOX6 compared to 40.0% with standard chemotherapy, with a median…

  • Interferon-High Immunophenotype and Immunotherapy Response in Colorectal Cancer

    A new study published in Cancer Cell, provides key insights into the role of the interferon-high (IFN-high) immunophenotype in predicting response to immune checkpoint inhibition (ICI) in colorectal cancer (CRC). By analyzing tumor microenvironment features, the study identifies a subset of both mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) CRCs that exhibit an IFN-high profile,…

  • Advancing mCRC Treatment: Alberto Sobrero’s Contributions to the IMPROVE Trial

    The IMPROVE trial, a phase II study investigating intermittent versus continuous panitumumab plus FOLFIRI in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC), has provided key insights into optimizing first-line treatment strategies.

  • Advancing Precision in Colon Cancer Prognostication: Insights from Professor Julien Taieb

    Recent research led by Professor Julien Taieb and colleagues provides significant advancements in the prognostic assessment of stage III colon cancer by integrating circulating tumor DNA (ctDNA) and Immunoscore (IS). This post hoc analysis of the PRODIGE-GERCOR IDEA-France and HORG-IDEA-Greece trials demonstrates that ctDNA serves as an independent prognostic marker, while IS provides additional stratification,…

  • Professor Rohit Loomba’s Contribution to Advancing MASH Pharmacological Research

    Professor Rohit Loomba played a pivotal role in a comprehensive network meta-analysis evaluating the efficacy of pharmacological therapies for fibrosis regression and MASH resolution. Published in Hepatology, this study analyzed…

  • Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials

    Professor Jerome Boursier played a leading role in a multi-center study evaluating non-invasive tests (NITs) for fibrotic MASH, published in JHEP Reports. This study addresses a critical challenge in MASH…

  • Refining Prognostic Models in Stage III Colon Cancer: Thierry André’s Contribution

    A groundbreaking study published in JCO introduces novel prognostic models leveraging transcriptomic signatures of the tumor microenvironment (TME) and cell cycle to enhance risk stratification in stage III colon cancer. Using data from the PETACC-8 and IDEA-France trials, researchers identified key markers, including T-cell and macrophage M2 signatures, CXCL13 expression, and an Oncotype-like recurrence score.